Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist
Leiden University Medical Center · The Netherlands Cancer Institute
Abstract
Sclerosteosis, a skeletal disorder characterized by high bone mass due to increased osteoblast activity, is caused by loss of the SOST gene product, sclerostin. The localization in bone and the mechanism of action of sclerostin are not yet known, but it has been hypothesized that it may act as a bone morphogenetic protein (BMP) antagonist. We show here that SOST/sclerostin is expressed exclusively by osteocytes in mouse and human bone and inhibits the differentiation and mineralization of murine preosteoblastic cells (KS483). Although sclerostin shares some of the actions of the BMP antagonist noggin, we show here that it also has actions distinctly different from it. In contrast to noggin, sclerostin did not…
Citation impact
- FWCI
- 8.44
- Percentile
- 100%
- References
- 46
Authors
10Topics & keywords
- Sclerostin
- Noggin
- Osteocyte
- Bone morphogenetic protein
- Osteoblast
- Internal medicine
- Endocrinology
- Chemistry